SynthesisBMC gastroenterology2026
Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) affects nearly 300 million people worldwide and is a leading cause of hepatocellular carcinoma (HCC). While cirrhosis is a risk factor for HCC, hepatitis B virus (HBV) DNA integration can lead to HCC in non-cirrhotic individuals. This study synthesized existing data to compare HCC risk among non-cirrhotic patients treated with antivirals versus those untreated.
methodsA systematic literature review was conducted. Databases were searched in February 2023 and handsearches were performed to identify studies reporting HCC incidence in non-cirrhotic CHB patients, both treated with antivirals for a mean or median duration of at least three years and untreated. A meta-analysis compared HCC incidence rates between treated and untreated populations.
resultsTwo thousand, one hundred sixty-four records were screened and 61 publications on 50 studies were included. HCC cumulative incidence rates increased with greater follow-up, ranging from 0 to 3% at one year and 0 to 30% at 10 years. Incidence rates ranged from 0 per 100 to 2.43 per 100 person-years. The comparative meta-analysis of four studies indicated that treated populations had a 40% reduction in HCC incidence compared to untreated groups (incidence rate ratio [IRR]: 0.59; 95% CI: 0.50, 0.69), with incidence rates expressed per 100 person-years. Sensitivity analyses confirmed the robustness of these findings.
conclusionsAntiviral therapy significantly reduces HCC risk in non-cirrhotic CHB patients. These results, with other literature, support treatment guideline expansion to include non-cirrhotic individuals and prevent HCC development. Further research is necessary to evaluate the impact of early versus late treatment initiation and explore potential differences between antivirals. SYSTEMATIC REVIEW REGISTRATION: PROSPERO ID: CRD42023396260. Date of registration: 11 April 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.